Oklahoma City, OK 73105
For Immediate Release: April 24, 2013
Sen. Greg Treat
Governor signs bill addressing cost disparity between oral,
intravenous cancer drugs
Gov. Mary Fallin has signed legislation to address
pricing disparities between orally and intravenously-administered
cancer medications. Sen.
Greg Treat, author of Senate Bill 765, explained that due to
certain insurance classifications, oral cancer medications may be
far more costly for patients than intravenous treatments, even when
the same medicines are used.
Treat said his legislation will establish parity in pricing for
medications that can potentially save lives.
“It simply isn’t right that obscure classifications
should result in drastically different price tags being attached
to identical cancer medications,” said Treat, R-Oklahoma City.
“This legislation restores fairness to the process. The bill
can also provide an important measure of hope for people who are
fighting cancer, and are balancing significant financial demands
as a result. I’m very grateful for the governor’s support
of the measure, and I’m pleased to see it signed into law.”
Treat noted that oral medications in many cases fall under prescription
drug coverage in insurance plans. Intravenous medicines, however,
may fall under a different classification and are often included
under medical coverage. As a result, orally administered medicines
may be vastly more expensive, despite the fact they may be easily
administered in the home, rather than a hospital or medical facility.
Rep. David Derby, House author of SB 765, praised the governor’s
signing of the proposal.
“This is a good bill that will bring us into line with what
20-plus states are doing around the country right now,” said
Derby, R-Owasso. “It allows individuals with insurance the
ability to have access to FDA-approved chemotherapy that their physician
recommended, regardless of how the chemotherapy is administered.”
For more information, contact:
Sen. Treat: (405) 521-5632